Health Economics And Outcomes Research Services: Market Size & Forecast 2026

Health Economics and Outcomes Research services provide the analytical foundation for pricing negotiations, reimbursement submissions, health-technology assessments, and lifecycle management of healthcare products. The market encompasses a broad range of activities, including cost-effectiveness modeling, budget-impact analysis, patient-reported outcomes measurement, observational database studies, and economic burden-of-illness research. While estimates of the 2025 market size vary by methodology, ranging from approximately $1.4 billion to $1.9 billion depending on scope, the consensus across industry analyses places it firmly above $1.7 billion, with most projections pointing to a market approaching or exceeding $3 billion by 2030 to 2035.

• •The market validates the clinical and economic worth of drugs, devices, and digital-health interventions to support reimbursement decisions
• •Valuation in 2025 clusters between $1.72 billion and $1.9 billion under standard service-scope definitions; broader market definitions that include software and platform solutions can yield notably higher figures
• •Projected CAGR across major industry estimates falls between 12% and 15% through the decade

Healthcare cost containment is a primary engine of HEOR demand, as governments and private payers increasingly require rigorous evidence before authorizing premium pricing for new therapies. The globalization of pharmaceutical launches means manufacturers must generate evidence tailored to multiple health-technology-assessment bodies, each with distinct methodological requirements, multiplying the volume of research required. Additionally, the growing adoption of value-based contracting, where reimbursement is tied directly to patient outcomes, creates a sustained need for ongoing post-market outcomes monitoring and economic modeling.

• •Value-based care and risk-sharing agreements between manufacturers and payers demand continuous, real-world evidence that traditional clinical trials alone cannot provide
• •Rising prevalence of chronic and complex conditions, such as oncology, immunology, and neurology therapies, raises the stakes and cost of demonstrating long-term clinical and economic value
• •Expanding regulatory and payer expectations in emerging markets across Asia-Pacific and Latin America are extending the geographic scope of HEOR activities

North America commands the largest share of the global HEOR services market, driven by a dense pharma and biotech R&D ecosystem, sophisticated payer expectations, and mature health-technology-assessment infrastructure. Europe follows, with a well-established HTA framework through agencies such as NICE and EUnetHTA that heavily influence HEOR investment. The Asia-Pacific region is the fastest-growing segment, reflecting rapid healthcare-system expansion, rising domestic pharma capability, and growing adoption of health economic evaluation in countries including China, South Korea, and Japan.

• •Service-type segmentation typically spans health economics modeling, real-world evidence generation, outcomes measurement, and market-access strategy consulting
• •End-user demand is led by large and mid-size pharmaceutical and biotechnology firms, followed by medical-device manufacturers and, increasingly, digital-health and diagnostics companies
• •Regional dominance reflects not only pharma concentration but also the rigor and standardization of local HTA and reimbursement processes

What are the recent trends and outlook?

The integration of artificial intelligence, machine learning, and advanced analytics into HEOR workflows is accelerating, enabling faster synthesis of real-world evidence and more granular patient-subgroup analyses. Digital biomarkers, wearable-generated health data, and patient-reported outcome measures collected through mobile platforms are expanding the data sources available for outcomes research. Looking ahead, the market is expected to consolidate modestly as larger CROs acquire boutique HEOR specialists, while ongoing demands for multi-country submissions and real-world evidence requirements will sustain double-digit growth through the decade.

• •AI-driven evidence synthesis, predictive modeling, and automation of routine economic-model inputs are reshaping HEOR operational efficiency
• •Real-world evidence, digital health data, and patient-centered outcomes are becoming increasingly central to HEOR deliverables as regulators and payers update guidance
• •Long-term market expansion is supported by structural trends in healthcare, aging populations, high-cost specialty therapies, and payers' persistent need for cost-containment tools